

Biologics

[Health & Medicine](#)



**ASSIGN
BUSTER**

Biologics Entity: Inovio Question Board of directors Dr. Kim Joseph Kim, Ph. D is the Director, President, and Chief Executive Officer of Inovio Pharmaceuticals. Before being appointed as the CEO of Inovio, Joseph co-founded VGX Pharmaceuticals in 2000 and led the company for nine years. In 2009, Dr. Kim joined Inovio Biomedical with VGX to form Inovio Pharmaceuticals. Dr. Joseph has a BSC degree in Chemical Engineering and Economics from MIT He has a Master of Business Administration Degree in Finance from the Wharton School and holds a Ph. D in Biochemical Engineering from the University of Pennsylvania.

Peter Kies

Before becoming the Chief Financial Officer of Inovio in 2002, Peter acquired a wide experience in the strategic and functional management of high technology and biotechnology companies. His experience include corporate growth, which includes from IPO to profitability. Mr. Peter holds a BSc. Degree in Business Administration from USIU (United States International University, San Diego).

Scientific Advisory Board

David B. Weiner, Ph. D.

David is a widely known leader in gene therapy, vaccines, and immunology. He has over 300 peer-reviewed journals as a leading forerunner in the DNA vaccines field. Before becoming chairman of Inovio Board of Directors, Weiner was an editor with several scientific published works like DNA Vaccine Meeting 2010, Biological active peptides, and Design, Synthesis and Utilization. Dr. Weiner has a Bachelor of Science in Biology from SUNY at Stony Brook and a M. S in Biology from university of Cincinnati.

Philip D. Greenberg, MD

<https://assignbuster.com/biologics/>

Dr. Philip is the Head of Program of immunology in Inovio Pharmaceuticals. He is also a professor of Medicine and immunology at University of Washington. Dr. Philip holds a degree in biology from Washington university. He worked at Fred Hutchinson Cancer Research Center. In 1971, he received his M. D. from the State University of New York.

Question 2

VGX-3100 is an experimental therapy that is designed to remove precancerous cervical lacerations. It also clears HPV infection with robust T cell responses. The therapy is administered depending on age and severity of HPV.

Question 3

The mechanism of action of VGX-3100 is that of inducing regression of precancerous cervical lesions. VGX-3100 is an immunotherapy that has two DNA plasmids that targets the E6 and E7 oncogenes of HPV category 16 and 18. The oncogenes are responsible for transformation of cells that are infected with HPV into precancerous cells.

Question 4

Study locations include the State of Florida, Boynton Beach and in Lakewood, Colorado in the United States.

Question 5

Inovio Pharmaceuticals has the quest of revolutionizing vaccines, therefore combing two technologies that are distinct. First, the company uses synthetic vaccines that are not only designed for prevention, but also treats diseases. Second, the company's electroporation vaccine delivery technology, which plays a crucial role in enabling fast body immune responses from the synthetic vaccines.

Reference

Inovio. (2015, April 1). Inovio . Retrieved from <http://www.inovio.com/>